截至二零二三年十二月三十一日止的經審核賬目

Futu NewsApr 30 02:40 ET · Announcements

Announcement Highlights | NIO's Q4 revenue increased 6.5% year on year to 17.103 billion yuan; Great Wall Motor's February sales increased 4.12% year on year

China Electric Power's combined total electricity sales volume in January was 10.3482 million megawatt-hours, an increase of 41.15% over the previous year; Shanghai Pharmaceutical: Norepinephrine bitartrate injection passed the generic drug consistency evaluation.

Gelonghui FinanceMar 5 19:08 ET

Announcement Highlights: NetEase Q4 net revenue increased 7% year-on-year to 27.14 billion yuan; Yuexiu Real Estate acquired land for 1,414 billion yuan

NetEase Cloud Music's revenue in 2023 was 7.87 billion yuan, turning a loss into a profit for the first time, and gross margin rose to 26.7%; Pacific Shipping had a turnover of US$2,297 billion in 2023, a year-on-year decrease of 30.02%.

Gelonghui FinanceFeb 29 19:19 ET

Selected Announcements | Country Garden was petitioned for liquidation by Ever Credit; China Exempts China to invest an additional 1.1 billion yuan in duty-free shopping

Nine Dragons Paper announced interim results, with shareholders accounting for a profit of 292 million yuan, turning a year-on-year loss into a profit; Fuzhikang Group issued a profit warning and expects a consolidated net loss of about US$120.8 million in 2023.

Gelonghui FinanceFeb 27 19:22 ET

Selected Announcements | Haohai Biotech's annual net profit to mother increased by 130% year-on-year; Zijin Mining's 17.5 billion yuan mine expansion project approved

Huahong Semiconductor: Net profit due to mother decreased by 35.64% year on year in 2023; Times Electric: net profit to mother increased by 21.51% year on year in 2023; BYD Chairman and CEO Wang Chuanfu proposed to repurchase A-shares to 400 million yuan.

Gelonghui FinanceFeb 25 19:04 ET

Selected Announcements | New Oriental and Yu Minhong promised to purchase a total of HK$700 million Dongfang Selected Shares; Yao Ming Joint Inc. expects adjusted net profit to increase by more than 100% last year

Saisheng Pharmaceutical: The Phase III clinical trial of Vaborem® in China completed the enrollment of all subjects; Xianruida Healthcare: The registration application for PERIDGE® was approved by the China National Drug Administration.

Gelonghui FinanceJan 31 19:27 ET